Antinuclear antibody testing: Methods, indications, and interpretation

Laboratory Medicine

Volumn 34, Issue 2, 2003, Pages 113-117

  Greidinger, Eric L ^a   Hoffman, Robert W ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN G;

ANALYTIC METHOD; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOFLUORESCENCE; LABORATORY TEST; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SYNDROME CREST;

EID: 0037328041     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/VUB9-0VTP-MEWV-3W0F     Document Type: Review

References (38)

1. Solomon DH, Shmerling RH, Schur PH, et al. A computer based intervention to reduce unnecessary serologic testing. J Rheumatol. 1999;26:2578-2584.
2. Ulvestad E. Performance characteristics and clinical utility of a hybrid ELISA for detection of ANA. APMIS. 2001;109:217-222.
3. Ulvestad E, Kanestrom A, Madland TM, et al. Evaluation of diagnostic tests for antinuclear antibodies in rheumatological practice. Scand J Immunol. 2000;52:309-315.
4. Roberts-Thompson P, McEvoy R, Gale R, et al. Quality assurance of immunodiagnostic tests in Australasia. Pathology. 1991;23:125-129.
5. Bizzaro N, Tozzoli R, Tonutti E, et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J Immunol Methods. 1998;219(1-2):99-107.
6. Jaskowski TD, Schroder C, Martins TB, et al. Screening for antinuclear antibodies by enzyme immunoassay. Am J Clin Pathol. 1996;105:468-473.
7. Emlen W. O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612-1618.
8. Homburger HA, Cahen YD, Griffiths J, et al. Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med. 1998;122:993-999.
9. Rondeel JM, van Gelder W. van der Leeden H, et al. Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked immunosorbent assay or both? Ann Clin Biochem. 1999;36 (Pt 2):189-195.
10. Bossuyt X. Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies. Clin Chem Lab Med. 2000;38:1033-1037.
11. Anderson JD, Wang GS, Johnson JC, et al. Autoantibody profile testing by immunodiffusion (ID) and hemagglutination (HA): comparison with routine immunofluorescent antinuclear antibody (FANA) testing. Arthritis Rheum. 1991;34 Suppl 1:8.
12. Weinstein A, Bordwell B, Stone B, et al. Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. Am J Med. 1983;74:206-216.
13. Aeschlimann A, Meyer O, Bourgeois P, et al. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis. 1989;48:992-997.
14. Avina-Zubieta JA, Galindo-Rodrigeuz G, KwanYeung L, et al. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus. 1995;4:370-374.
15. Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 1999;42:455-464.
16. Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol. 2002;29:68-74.
17. Robinson WH, DiGennaro C, Hueber W, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002;8:295-301.
18. Robinson WH, Steinman L, Utz PJ. Proteomics technologies for the study of autoimmune disease. Arthritis Rheum. 2002;46:885-893.
19. Swaak AJ, Huysen V, Smeek RJ. Antinuclear antibodies in routine analysis: the relevance of putative clinical associations. Ann Rheum Dis. 1993;52:110-114.
20. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford). 2000;39:1316-1319.
21. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601-1611.
22. Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999;42:46-50.
23. Richardson B, Epstein WV. Utility of the fluorescent antinuclear antibody test in a single patient. Ann Intern Med. 1981;95:333-338. Review.
24. Barnett AJ, McNeilage LJ. Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses. Ann Rheum Dis. 1993;52:365-368.
25. Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899-909.
26. Cervera R, Font J, Ramos-Casals M, et al. Primary Sjogren's syndrome in men: clinical and immunological characteristics. Lupus. 2000;9:61-64.
27. Petri M, Karlson EW, Cooper DS, et al. Autoantibody tests in autoimmune thyroid disease: a casecontrol study. J Rheumatol. 1991;18:1529-1531.
28. Charles PJ, Smeenk RJT, DeJong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in openlabel and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-2390.
29. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997;26:561-566.
30. Medina-Rodriguez F, Guzman C, Jara LJ, et al. Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: a study of 2 populations with similar risk factors. J Rheumatol. 1993;20:1880-1884.
31. Cassidy JT, Sullivan DB, Petty RE. Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2 Suppl):224-227.
32. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32(1 Suppl):181-197.
33. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13:911-916.
34. Vlachoyiannopoulos PG, Drosos AA, Wiik A, et al. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993;32:297-301.
35. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998;114:801-807.
36. Ho A, Magder LS, Barr SG, et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2342-2349.
37. Koh WH, Dunphy J, Whyte J, et al. Characterisation of anticytoplasmic antibodies and their clinical associations. Ann Rheum Dis. 1995;54:269-273.
38. Sanchez-Guerrero J, Lew RA, Fossel AH, et al. Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996;39:1055-1061.